Delving into the Latest Updates on [F-18] RDG-K5 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs, Diagnostic radiopharmaceuticals

Synonyms

[18F] fluorine arginine-glycine-aspartic, [F-18]RGD-K5

Target-

Action

enhancers

Mechanism

PET imaging(Positron-emission tomography enhancers)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication-

Inactive Indication

Carotid Stenosis

Originator Organization

The Cleveland Clinic Foundation

Active Organization-

Inactive Organization

The Cleveland Clinic Foundation

License Organization-

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

The purpose of this study is to investigate the ability of the compound[F-18]RGD-K5, when used as a tracer during PET (positron emission tomography) imaging, to detect regions of unstable atherosclerotic plaque in the carotid artery of subjects being considered for carotid endarterectomy (CEA),and to confirm this ability through histological studies of samples of carotid artery plaques that will be collected during the planned carotid surgery.

Start Date31 Oct 2013

Sponsor / Collaborator

The Cleveland Clinic Foundation

NCT01602471

/ TerminatedPhase 2

An Exploratory, Phase II, Open Label, Single-Center, Non-Randomized Study Of [F-18] RGD-K5 Positron Emission Tomography (PET) In Participants With Carotid Artery Stenosis

This trial will be the first trial for the Investigation Product (IP), [F-18]RGD-K5 for carotid plaque imaging and will be conducted as a Phase II trial since this compound has already been tested in humans for phase I and phase II imaging. All study results will be evaluated and analyzed in order to consider the design for future clinical trials.

Start Date30 Apr 2012

Sponsor / Collaborator

Siemens Molecular Imaging, Inc.

EUCTR2010-018874-19-BE

/ Not yet recruitingPhase 2

A phase II, open label, non-randomized, multi-center, pilot, efficacy study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a tool to monitor response to an anti-angiogenic drug.

Start Date02 Aug 2010

Sponsor / Collaborator

Siemens Molecular Imaging, Inc.

100 Clinical Results associated with [F-18] RDG-K5

Login to view more data

100 Translational Medicine associated with [F-18] RDG-K5

Login to view more data

100 Patents (Medical) associated with [F-18] RDG-K5

Login to view more data

100 Deals associated with [F-18] RDG-K5

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Carotid Stenosis	Phase 2	United States	The Cleveland Clinic Foundation	01 Nov 2013

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01968226 (TRACER, CTgov)	Phase 2	Carotid Stenosis	3	[F-18] RDG-K5	cvaheqlhde(zjyazqidck) = vazrckggqo mgpplgumnt (zrevjcvtfv, dajcggdedq - clunzaqrhi) View more	-	10 Aug 2017
NCT01602471 (CTgov)	Phase 2	Carotid Stenosis	5	[F-18]RDG-K5	xxyrqqripe(yhnljvnvaq) = ovpnmvijgs nsfvlzdeah (nqtmaqkuck, nwrooalyjg - swmajhymnl) View more	-	27 Sep 2013
NCT00743353 (Pubmed \| J Nucl Med)	Early Phase 1	Sarcoma \| Lung Cancer \| Breast Cancer ... View more	-	18F-RGD-K5 (Rhesus monkeys)	ruyznvokuy(ocqugbqmnu) = 12 eljgvsocri (qeeuecggdq )	-	01 May 2012
NCT00743353 (Pubmed \| J Nucl Med)	Early Phase 1	Sarcoma \| Lung Cancer \| Breast Cancer ... View more	-	18F-RGD-K5 (Healthy humans)	ruyznvokuy(ocqugbqmnu) = 12 eljgvsocri (qeeuecggdq )	-	01 May 2012